Phio Pharmaceuticals Corp. (PHIO): who owns it and who trades it
As of Nov 16, 2026, PHIO insiders reported 18 purchases worth $147K in the last 12 months. The largest buyer was Robert J Bitterman (CEO), with $65.4K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Phio Pharmaceuticals
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, PHIO insiders reported $147K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | David H Deming | Director | Purchase | 3,000 | $0.83 | $2.5K | Form 4 |
| Nov 12, 2026 | David H Deming | Director | Purchase | 9,000 | $0.81 | $7.3K | Form 4 |
| Nov 11, 2026 | David H Deming | Director | Purchase | 5,200 | $0.84 | $4.4K | Form 4 |
| Nov 10, 2026 | David H Deming | Director | Purchase | 6,800 | $0.84 | $5.7K | Form 4 |
| Nov 9, 2026 | Robert J Bitterman | CEO | Purchase | 25,000 | $0.82 | $20.5K | Form 4 |
| Nov 9, 2026 | Ronald Todd Plott | Director | Purchase | 18,300 | $0.83 | $15.2K | Form 4 |
| Sep 29, 2026 | Ronald Todd Plott | Director | Purchase | 5,000 | $1.04 | $5.2K | Form 4 |
| Sep 28, 2026 | Ronald Todd Plott | Director | Purchase | 5,000 | $1.03 | $5.2K | Form 4 |
| Sep 24, 2026 | Patricia A Bradford | Director | Purchase | 6,500 | $1.01 | $6.6K | Form 4 |
| Sep 22, 2026 | Robert J Bitterman | CEO | Purchase | 2,000 | $1.03 | $2.1K | Form 4 |
| Sep 15, 2026 | Patricia A Bradford | Director | Purchase | 12,000 | $1.03 | $12.4K | Form 4 |
| Aug 19, 2026 | Ronald Todd Plott | Director | Purchase | 15,000 | $1.14 | $17.1K | Form 4 |
| Aug 18, 2026 | Robert J Bitterman | CEO | Purchase | 10,000 | $1.06 | $10.6K | Form 4 |
| Jun 26, 2026 | Robert J Bitterman | CEO | Purchase | 10,000 | $0.99 | $9.9K | Form 4 |
| Dec 31, 2025 | Robert J Bitterman | CEO | Purchase | 5,000 | $1.03 | $5.2K | Form 4 |
| Dec 23, 2025 | Robert J Bitterman | CEO | Purchase | 5,000 | $1.02 | $5.1K | Form 4 |
| Nov 21, 2025 | Robert J Bitterman | CEO | Purchase | 5,000 | $1.14 | $5.7K | Form 4 |
| Nov 18, 2025 | Robert J Bitterman | CEO | Purchase | 5,000 | $1.27 | $6.3K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Robert J Bitterman | Chairman, Pres. & CEO, Director | $65.4K | – | Nov 9, 2026 |
| Ronald Todd Plott | Director | $42.6K | – | Nov 9, 2026 |
| David H Deming | Director | $19.9K | – | Nov 13, 2026 |
| Patricia A Bradford | Director | $18.9K | – | Sep 24, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
PHIO short interest
Low short interest. 0.7% of PHIO shares are sold short: about 1 share in 135. Over the last 12 reports the number of shares short went down 74%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 86,344 PHIO shares were sold short, 0.7% of the shares outstanding, down 36.7% from the report before. At the average daily volume of 57,867 shares, buying them all back would take about 1.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 86,344 | 0.74% | -37% | 57,867 | 1.5 |
| Oct 15, 2026 | 136,375 | 1.17% | +52% | 91,870 | 1.5 |
| Sep 30, 2026 | 89,454 | 0.77% | -40% | 114,595 | 1.0 |
| Sep 15, 2026 | 149,890 | 1.29% | -32% | 155,806 | 1.0 |
| Aug 31, 2026 | 221,546 | 1.91% | -31% | 222,994 | 1.0 |
| Aug 14, 2026 | 319,747 | 2.75% | +11% | 121,439 | 2.6 |
| Jul 31, 2026 | 287,349 | 2.47% | +62% | 305,619 | 1.0 |
| Jul 15, 2026 | 177,615 | 1.53% | -19% | 2.62M | 1.0 |
| Jun 30, 2026 | 218,725 | 1.88% | -28% | 241,492 | 1.0 |
| Jun 15, 2026 | 302,481 | 2.60% | -4% | 153,874 | 2.0 |
| May 29, 2026 | 313,798 | 2.70% | -5% | 106,065 | 3.0 |
| May 15, 2026 | 331,567 | 2.85% | -29% | 177,265 | 1.9 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Phio Pharmaceuticals company events
Phio Pharmaceuticals filed 15 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 13, 2026AnnouncementThe Company issued a press release announcing the successful completion of its first commercial-scale cGMP Batch of PH-762 drug substance, a key operational milestone that supports the planned initiation of the Company's Phase 2b clinical trial in the first quarter of 2027. Filing
- Sep 28, 2026LeadershipPhio Pharmaceuticals Corp. held its 2026 Annual Meeting of Stockholders via live webcast on September 28, 2026. Filing
- Sep 14, 2026AnnouncementThe Company issued a press release announcing a key development milestone for PH-762, including the submission of materials to the FDA to support the next phase of clinical development in cutaneous cell carcinoma and a planned Phase 2b neoadjuvant study. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 21, 2026LeadershipThe Board of Directors of Phio Pharmaceuticals Corp. increased the size of the Board to six members and appointed R. Todd Plott, M.D. to serve on the Board until the 2026 annual meeting of stockholders. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Apr 8, 2026AgreementPhio Pharmaceuticals Corp. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, shares of the Company’s common stock, par value $0.0001 per share. Filing
- Mar 30, 2026AnnouncementPhio Pharmaceuticals Corp. issued a press release announcing it has entered into a cGMP drug product manufacturing services agreement with a U.S. manufacturer for clinical supply. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Feb 18, 2026LeadershipReported a change among its top officers or directors, or their pay. Filing
- Feb 10, 2026AnnouncementThe Company issued a press release announcing the Safety Medical Committee's formal conclusion with respect to the Company's Phase 1b clinical trial of PH-762 and updates with respect to the clinical trial’s response rates. Filing
- Jan 20, 2026AnnouncementThe Company issued a press release announcing key tumor response data from all cohorts in their intratumoral PH-762 dose escalation cutaneous carcinoma trial. Filing
- Dec 23, 2025AnnouncementThe Company issued a press release announcing a significant step forward in its drug development program for PH-762 with the acceptance of its nonclinical protocol study design by the Federal Drug Administration (FDA). Filing
- Nov 25, 2025AnnouncementThe Company issued a press release announcing the completion of enrollment in its ongoing Phase 1b clinical trial (NCT 06014086) of INTASYL siRNA Lead Compound PH-762. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Phio Pharmaceuticals financials
Famous investors that hold PHIO
2 of the 50 well-known investors we track reported holding PHIO in their latest 13F filing. The largest position is Ken Griffin's, worth $67.7K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 65,686 | $67.7K | 0.0% | +39% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 57,377 | $59.1K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named PHIO in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
Questions about Phio Pharmaceuticals Corp. (PHIO) stock
Are PHIO insiders buying or selling?
In the last 12 months, PHIO insiders reported 18 open-market purchases worth $147K and no sales. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in PHIO?
As of Oct 30, 2026, 86,344 PHIO shares were sold short, 0.7% of the shares outstanding, down 36.7% from the report before. At the average daily volume of 57,867 shares, buying them all back would take about 1.5 trading days (days to cover). See the history.
Which famous investors hold PHIO?
2 of the 50 well-known investors we track reported PHIO in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $67.7K. See all holders.
Executive pay
Phio Pharmaceuticals's chief executive was paid a total of $1.2M for the year ended Dec 31, 2025, up 200% from $387K the year before. In the last 12 months, Phio Pharmaceuticals's executives and directors bought $147K of stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.